Dizal Pharmaceuticals’ compound was also evaluated in murine models of prostate cancer, where treatment with the novel antagonist and anti-PD-1 significantly reduced tumor volume compared to monotherapy[85]. The gene discussed is PDCD1; the disease is neoplasm.